Desmopressin
/ Synthetic analog of vasopressin; selective V2-receptor agonistALIAS · DDAVP · 1-deamino-8-D-arginine vasopressin
Terms in this page you can click for a plain-English popup: , , , , , , , .
FDA-approved for diabetes insipidus, nocturia, hemophilia A, and von Willebrand disease type I.
Desmopressin is a synthetic analog of arginine vasopressin with two modifications (deamination at position 1 and D-Arg at position 8) that confer selectivity for V2 receptors and resistance to enzymatic degradation. Acts on renal collecting duct V2 receptors to increase water reabsorption, and on vascular endothelium to release von Willebrand factor and factor VIII.
Extensive. FDA-approved indications established through decades of clinical use: central diabetes insipidus, primary nocturnal enuresis, nocturia with overnight polyuria, hemophilia A, von Willebrand disease type I.
The most important adverse event is hyponatremia, which can be severe and symptomatic. Labeling includes boxed warnings and fluid-intake guidance. Other AEs include headache, nausea, and nasal irritation (intranasal form).
Regulatory status
- FDA status:
- FDA-approved
- Compounding:
- Not eligible for compounding (approved, not in shortage)